FLXfit Post Market Outcome Study Protocol

NCT ID: NCT02882243

Last Updated: 2022-07-27

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 40 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2016-07-31
• Study Completion Date: 2022-07-31

Brief Summary

This investigation will provide safety and effectiveness information on the use of the FLXfit™ Cage. Data will be used for Post Market follow-up of the FLXfit™ system by evaluating:

• Safety as measured by the rate of serious operative and post-operative complications.
• Patients' quality of life, measured by health-related quality of life questionnaires up to 24 months following the procedure, as compared to patient's baseline.

Detailed Description

Interbody fusion in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. Patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). Patients should be skeletally mature and have completed six months of non-operative treatment

Conditions

Degenerative Disc Disease Lumbar

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

FLXfit Cage for fusion

Evaluating patient outcomes and radiographic outcomes

Intervention Type: DEVICE

Other Intervention Names

Transforaminal Interbody Fusion

Eligibility Criteria

Inclusion Criteria

• Adult (age 18 - 70 years) patient (male or female) with the following conditions of the lumbar spine as confirmed by advanced imaging (CT or MRI), who is a candidate for primary spinal fusion procedure according to acceptable criteria for such medical conditions:

• Degenerative disc disease
• With up to Grade I spondylolisthesis
• Failure of at least 6 month conservative treatment BMI < 40.
• Patient to approve no pregnancy during the 24 months of study and no participation in other studies in parallel to this one.

Exclusion Criteria

• This device is not intended for cervical spine use. PI may exclude patient from study

Contraindications include, but are not limited to:

• Infection, local to the operative site
• Signs of local inflammation,
• Fever or leukocytosis,
• Morbid obesity,
• Pregnancy,
• Mental illness,
• Any other condition which would preclude the potential benefit of spinal implant surgery, such as the presence of tumors or congenital abnormalities, fracture local to the operating site, elevation of segmentation rate unexplained by other diseases, elevation of white blood count (WBC), or a marked left shift in the WBC differential count,
• Suspected or documented allergy or intolerance to implant's materials,
• Any case not described in the indications,
• Any patient unwilling to cooperate with postoperative instructions.
• These devices must not be used for pediatric cases, nor where the patient still has general skeletal growth.
• Any case where the implant components selected for use would be too large or too small to achieve a successful result.
• Any patient having inadequate tissue coverage over the operative site or inadequate bone stock or quality.
• Any patient in which implant utilization would interfere with anatomical structures or expected physiological performance.
• Prior fusion at the level to be treated.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CoreLink, LLC

UNKNOWN

Sponsor Role: collaborator

Foundation for Orthopaedic Research and Education

OTHER

Sponsor Role: lead

Responsible Party

Marc Weinstein

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

20-CL-027

Identifier Type: -

Identifier Source: org_study_id